Compare iShares Russell 2000 ETF (IWM) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares Russell 2000 ETF trades at $271.83 (market cap $75.59B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M). The key difference: iShares Russell 2000 ETF is far larger — about 77.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and iShares Russell 2000 ETF is more actively traded (37,947,395 versus 2,742,564). Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IWM | MRVI | |
|---|---|---|
Market Cap | $75.59B | $977.37M |
Volume | 37,947,395 | 2,742,564 |
52-Week High | $305.06 | $9.00 |
52-Week Low | $229.13 | $2.83 |
Typical Hold Time | 83 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $276.71, down 0.42% amid bearish technical signals with 15 sell indicators versus 2 buy signals. The ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to the S&P 500 over the past decade. Recent news highlights concerns about small-cap risk premiums and competition from more selective small-cap funds.
The outlook remains challenged by interest rate sensitivity and broader market rotation away from small caps. While offering diversification from large-cap tech concentration, IWM's inclusion of unprofitable companies presents fundamental risks. Near-term performance depends on Fed policy clarity and small-cap earnings resilience.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
